Genentech, Inc.

Genentech, Inc.

Genentech, Inc. is a leading biotechnology corporation that was founded in 1976 by Herbert Boyer and Robert A. Swanson. It is headquartered in South San Francisco, California, and is considered one of the pioneers in the field of recombinant DNA technology.

History

Genentech was established with the vision of using genetic engineering to develop new medicines. The company achieved a significant milestone in 1978 when it successfully produced human insulin using recombinant DNA technology, marking the first time a human protein was manufactured in a microorganism. This breakthrough led to the development of the first recombinant DNA drug, Humulin, which was approved by the U.S. Food and Drug Administration (FDA) in 1982.

In 2009, Genentech became a wholly owned subsidiary of Roche, a Swiss multinational healthcare company. Despite this acquisition, Genentech continues to operate as an independent center within Roche, focusing on research and early development.

Research and Development

Genentech is renowned for its innovative research and development in the field of biotechnology. The company has developed several groundbreaking therapies, particularly in the areas of oncology, immunology, and neuroscience.

Oncology

Genentech has been at the forefront of cancer treatment, developing several important cancer drugs. Notable products include:

• Rituxan (rituximab) - used to treat certain types of non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
• Herceptin (trastuzumab) - a monoclonal antibody used to treat HER2-positive breast cancer.
• Avastin (bevacizumab) - used to treat various types of cancer by inhibiting angiogenesis.

Immunology

In the field of immunology, Genentech has developed therapies for autoimmune diseases such as:

• Xolair (omalizumab) - used to treat allergic asthma and chronic idiopathic urticaria.
• Actemra (tocilizumab) - used for rheumatoid arthritis and systemic juvenile idiopathic arthritis.

Neuroscience

Genentech is also involved in developing treatments for neurological disorders, including:

• Ocrevus (ocrelizumab) - used to treat multiple sclerosis.

Corporate Culture and Social Responsibility

Genentech is known for its unique corporate culture, which emphasizes scientific innovation, collaboration, and a commitment to improving patient lives. The company has been recognized as one of the best places to work in the biotechnology industry.

Genentech is also committed to social responsibility, engaging in various initiatives to improve access to medicines, support community health, and promote environmental sustainability.

See Also

• Biotechnology
• Pharmaceutical industry
• Roche

References

• "Genentech: A History of Innovation". Retrieved October 10, 2023.